To include your compound in the COVID-19 Resource Center, submit it here.

Korean company ABL out-licenses antibody programs to U.S.

ABL Bio Inc. (Seongnam, South Korea) granted Trigr Therapeutics Inc. (Irvine, Calif.) global rights to five

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE